Beximco Pharmaceuticals Ltd Beximco Pharma wins at Scrip Awards 2017
30 November 2017 - 9:30PM
RNS Non-Regulatory
TIDMBXP
Beximco Pharmaceuticals Ltd
30 November 2017
30 November 2017
BEXIMCO PHARMACEUTICALS LTD.
Beximco Pharma wins Best Company in an Emerging Market at the
2017 Scrip Awards
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces that the Company has won the award for
the 'Best Company in an Emerging Market' at the Scrip Awards,
presented in London, England, on 29 November 2017. Rabbur Reza,
Chief Operating Officer of Beximco Pharma, accepted the award on
behalf of the Company.
In its 13th year, the Scrip Awards programme recognises the key
roles that pharmaceutical, biotech and other related industries
play in improving healthcare around the world. The awards provide
the industry with an opportunity to acknowledge its highest
achievers across all parts of the value chain and to recognise both
corporate and individual achievement. A panel of 16 highly
respected and independent judges from across diverse sectors
evaluated the award entries to select the finalists.
Beximco Pharma Managing Director, Mr Nazmul Hassan MP,
commented:
"I am honoured and excited that Beximco Pharma has been selected
as the 'Best Company in an Emerging Market' at the prestigious
Scrip Awards. As a Company that is currently exporting products to
over 50 countries and producing more than 500 products encompassing
broad therapeutic categories, Beximco Pharma is continuing to
expand its reach and impact around the world. As the only Company
in Bangladesh to export pharmaceutical products to the US, we are
setting a high standard for the pharmaceutical industry in
Bangladesh. I look forward to our continued advancement as we
strengthen our research and development capabilities, create new
partnerships and build our presence in both domestic and
international markets."
For further information please visit www.beximco-pharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Gerry Beaney / Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,500 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others. The
Company's products are sold to retail outlets, medical institutions
and other pharmaceutical manufacturers in Bangladesh, in regional
markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and
Myanmar and in other markets overseas, principally in South East
Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia,
Philippines and Hong Kong; Africa, including South Africa,
Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central
Asia, including Azerbaijan; Middle East, including Kuwait and
Jordan; Pacific Island countries; Latin and Central American
countries; Europe, including Austria, Germany and Romania;
Australia and North America, including the USA and Canada.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAWGGQPGUPMGUU
(END) Dow Jones Newswires
November 30, 2017 05:30 ET (10:30 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024